Journal: PLOS ONE

Article Title: PAI-1 mediates acquired resistance to MET-targeted therapy in non-small cell lung cancer

doi: 10.1371/journal.pone.0300644

Figure Lengend Snippet: (A) EBC-1, H1993 parental, and resistant cells were treated with crizotinib, tepotinib, and cabozantinib for 72 h, and cell viability was measured using an MTS assay. Each experiment was assayed in six replicates, and the average IC 50 values (μM ± SD) were calculated from three independent experiments. (B) Morphological changes in parental and resistant cell lines were observed under a light microscope, and features were noted (40× magnification, light microscope). (C) Copy number assay on MET gene. The MET gene copy number was determined in human genomic DNA (HGD) and EBC-1 and H1993 parental and resistant cell lines. The copy number of each cell line with relative to the HGD copy number of 2 was presented, using the LINE-1 gene as endogenous control. (D) Protein expression analysis by Western blot in all parental and resistance cell lines. MET downstream signaling pathway markers were identified as any activation with or without crizotinib treatment. The cells were treated with crizotinib 1 μM for 2 h and subjected to immunoblotting. (E) Supervised hierarchical clustering analysis among the highly expressed significant 189 genes, which showed a significant difference with a p -value of less than 0.05 in parental cell lines compared with resistant cell lines. p- (Phosphorylated-), SD–standard deviation, NA–not applicable.

Article Snippet: Crizotinib (PF-02341066), cabozantinib (XL184), trametinib (GSK1120212), and tiplaxtinin (PAI0-039) were purchased from Selleck Chemicals (Houston TX, USA), and tepotinib (CAS1103508-80-0) was purchased from TargetMol (Massachusetts, United States).

Techniques: MTS Assay, Light Microscopy, Control, Expressing, Western Blot, Activation Assay, Standard Deviation

Journal: Journal of Clinical Medicine

Article Title: Lung Cancer with Brain Metastasis—Treatment Strategies and Molecular Characteristics

doi: 10.3390/jcm13237371

Figure Lengend Snippet: Clinical trials evaluating intracranial activity of TKIs in advanced NSCLC.

Article Snippet: VISION [ ] , Phase II , METex 14 skipping , 161/advanced NSCLC/43 had BMs , Neurologically stable and glucocorticoid dose was being tapered down, or untreated asymptomatic BM. , Tepotinib , ORR: 54.7% (95% CI 46.6–62.5) mPFS 13.8 m (95% CI 10.4-NE) , IC ORR: 66.7% (95% CI 38.4–88.2) IC mPFS: 20.9 m (95% CI 5.7-NE).

Techniques: Clinical Proteomics, Activity Assay, Control

Journal: JRSM Open

Article Title: The UK's Early Access to Medicines Scheme 10 years on: an evaluation using publicly available data

doi: 10.1177/20542704251317916

Figure Lengend Snippet: Drugs submitted to EAMS.

Article Snippet: 13 , Tepotinib , Tepmetko , Advanced non-small cell lung cancer , Merck Serono.

Techniques: Infection, Mutagenesis, Translocation Assay

Journal: Journal of Cancer Research and Clinical Oncology

Article Title: Advances in clinical research of MET exon 14 skipping mutations in non-small cell lung cancer

doi: 10.1007/s00432-025-06115-y

Figure Lengend Snippet: Past or ongoing clinical studies of NSCLC with METΔ14ex

Article Snippet: Tepotinib (Ib) , VISION (Globenewswire ) , NCT02864992 , II , 99 , ORR: 46% mPFS: 8.5 , Peripheral edema nausea.

Techniques:

Journal: Journal of Cancer Research and Clinical Oncology

Article Title: Advances in clinical research of MET exon 14 skipping mutations in non-small cell lung cancer

doi: 10.1007/s00432-025-06115-y

Figure Lengend Snippet: When and by country the medicines are available

Article Snippet: Tepotinib (Ib) , VISION (Globenewswire ) , NCT02864992 , II , 99 , ORR: 46% mPFS: 8.5 , Peripheral edema nausea.

Techniques:

Journal: OncoTargets and therapy

Article Title: Targeting the MET-Signaling Pathway in Non-Small–Cell Lung Cancer: Evidence to Date

doi: 10.2147/OTT.S219959

Figure Lengend Snippet: Agents Being Evaluated as Treatments for Non-Small–Cell Lung Cancers

Article Snippet: Tepotinib (EMD1214063, MSC2156119J; Merck), an oral, ATP-competitive, and highly selective MET inhibitor, was evaluated in a phase II study on patients with METex14-mutated NSCLCs.

Techniques:

Journal: OncoTargets and therapy

Article Title: Targeting the MET-Signaling Pathway in Non-Small–Cell Lung Cancer: Evidence to Date

doi: 10.2147/OTT.S219959

Figure Lengend Snippet: Clinical Trials on NSCLC Patients Without EGFR -Mutation(s)

Article Snippet: Tepotinib (EMD1214063, MSC2156119J; Merck), an oral, ATP-competitive, and highly selective MET inhibitor, was evaluated in a phase II study on patients with METex14-mutated NSCLCs.

Techniques: Mutagenesis, Over Expression, Amplification

Journal: OncoTargets and therapy

Article Title: Targeting the MET-Signaling Pathway in Non-Small–Cell Lung Cancer: Evidence to Date

doi: 10.2147/OTT.S219959

Figure Lengend Snippet: Clinical Trials on Patients with EGFR -Mutated NSCLC

Article Snippet: Tepotinib (EMD1214063, MSC2156119J; Merck), an oral, ATP-competitive, and highly selective MET inhibitor, was evaluated in a phase II study on patients with METex14-mutated NSCLCs.

Techniques: Amplification, Over Expression

Journal: Pharmaceuticals

Article Title: Relevance of Circulating Tumor Cells as Predictive Markers for Cancer Incidence and Relapse

doi: 10.3390/ph15010075

Figure Lengend Snippet: FDA-approved liquid biopsy tests for companion diagnostics.

Article Snippet: ArcherDx’s ArcherMET Assay , tepotinib (Tepmetko, Merck KGaA) , NSCLC/plasma , MET (exon 14 skipping) , , , Next-generation sequencing , Archer.

Techniques: Diagnostic Assay, Mutagenesis, Real-time Polymerase Chain Reaction, Next-Generation Sequencing